4 stories mentioning BOM:500124Updated 3m ago
Every FINWIRES story that references BOM:500124, newest first.
Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has an average rating of hold and mean price target of 1,335.44 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has received a notice of compliance (NOC) from the Canadian regulator, the Pharmaceutical Drugs Directorate (Health Canada), approving its generic Semaglutide Injection, according to a Wednesday filing to the Indian stock exchanges.The issuance of the NOC authorizes the commercialization, sale and distribution of the diabetes control drug Semaglutide Injection in Canada. The market authorization covers the 2 mg/pen (in 1.34 mg/mL) and 4 mg/pen (1.34 mg/mL).The active pharmaceutical ingredient is entirely produced in-house by Dr. Reddy's, with finished product manufacturing currently carried out by the company's manufacturing partner, OneSource Specialty Pharma (NSE:ONESOURCE, BOM:544292).Dr. Reddy's shares were down nearly 1% in recent trade.
Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has received a notice of compliance (NOC) from the Canadian regulator, Pharmaceutical Drugs Directorate (Health Canada), approving its generic Semaglutide Injection, according to a Wednesday filing to the Indian stock exchanges.The issuance of the NOC authorizes the commercialization, sale, and distribution of the diabetes control drug Semaglutide Injection in Canada. The market authorization covers the 2 mg/ pen (in 1.34 mg / mL) and 4 mg/pen (1.34 mg / mL).The active pharmaceutical ingredient is entirely produced in-house by Dr. Reddy's, with finished product manufacturing currently carried out by the company's manufacturing partner, OneSource Specialty Pharma (NSE:ONESOURCE, BOM:544292).The company's shares were down nearly 1% in recent trade.
Dr. Reddy's Laboratories' (NSE:DRREDDY, BOM:500124) board will meet on May 12 to consider the payment of a final dividend for fiscal 2026 ended March 31, according to an Indian bourse filing on Thursday.
